Today: 29 April 2026
Cloudflare stock leaps on Clawdbot AI agent buzz as NET traders look to Feb. 10 earnings

Cloudflare stock leaps on Clawdbot AI agent buzz as NET traders look to Feb. 10 earnings

NEW YORK, January 27, 2026, 18:19 EST — After-hours

Cloudflare Inc shares were last up 8.8% at $205.95 in after-hours trading on Tuesday. The move capped a sharp two-day run tied to online buzz around “Clawdbot,” an open-source AI agent that has been making the rounds in developer circles. Investing.com

Why it matters now: markets are primed to chase anything that hints at the next leg of AI spending. “Agentic” AI — tools built to take actions on their own, not just answer prompts — could translate into more automated web traffic, more security checks, and more demand for the plumbing that keeps it all running.

Cloudflare reports fourth-quarter results on Feb. 10 after the U.S. market closes, and will host a conference call at 5:00 p.m. Eastern. Investors are looking for evidence that the current surge in attention is turning into usage and guidance, not just talk on social media.

The chatter has centered on Clawdbot, built on Anthropic’s Claude, which runs locally on devices but leans on Cloudflare’s low-latency network to connect securely and operate at speed. Wolfe Research analyst Joshua Tilton wrote that “NET is positioned to capture that activity” as agents scale and make more API calls — software requests sent to other services. CEO Matthew Prince told analysts in October that about 80% of leading AI companies already use Cloudflare’s infrastructure: “The agents of the future will inherently have to pass through our network and abide by its rules,” he said. Reuters

Cloudflare rose 9.17% on Monday and added another 8.77% on Tuesday, closing at $205.95. The stock traded between $205.20 and $218.22 in regular hours, with about 12.5 million shares changing hands.

Cloudflare sells security and performance tools through an “edge” network — servers placed close to end users to reduce delays and filter attacks. Its usage-driven model means higher traffic can lift billable requests, making the idea of task-running AI agents roaming the web an easy story for traders to grab.

The company’s core business still overlaps with content-delivery and edge-security peers such as Akamai and Fastly, even as Wall Street tries to frame Cloudflare as AI infrastructure. That framing can shift fast.

There are risks. Buzz-driven rallies can unwind just as quickly, and investors will want proof the hype translates into paying workloads. Cloudflare’s own status page on Tuesday flagged intermittent elevated errors and timeouts for D1 databases and SQLite-backed Durable Objects, along with network degradation in Chicago that engineers were working to fix — reminders that execution and reliability stay in the frame.

Next up is Feb. 10: results after the close and a 5 p.m. ET call. Traders will be listening for any AI-linked lift in demand — and for what Cloudflare says about growth into 2026.

Stock Market Today

  • Nasdaq Futures Rise Ahead of Fed Decision and Major Tech Earnings
    April 29, 2026, 9:10 AM EDT. Nasdaq futures gained 0.4% ahead of the Federal Reserve's policy decision and earnings reports from tech giants Alphabet, Microsoft, Amazon, and Meta. Markets are cautious following a broad sell-off in major indices driven by chip stock weakness linked to slowing growth at AI firm OpenAI. Investors await the Fed's stance on inflation and interest rates, with crude oil prices rising amid unresolved US-Iran tensions. The Fed is expected to hold rates steady in Jerome Powell's final meeting before his replacement, Kevin Warsh, awaits Senate approval. Key focus remains on AI capital expenditure and the potential for further rate hikes in 2024. Earnings from AbbVie, AstraZeneca, Total Energies, UBS, and GSK are also in focus.

Latest article

Regeneron Earnings Beat, But Eylea Still Clouds REGN Stock

Regeneron Earnings Beat, But Eylea Still Clouds REGN Stock

29 April 2026
TARRYTOWN, New York, April 29, 2026, 09:02 EDT Regeneron Pharmaceuticals beat Wall Street’s first-quarter revenue and profit estimates on Wednesday, as growth in Dupixent and cancer drug Libtayo helped offset a weaker showing from its Eylea eye-drug franchise. Its shares were down 1.1% in premarket trading. The result matters now because Regeneron is trying to prove it can keep growing while its older Eylea product faces pressure from cheaper versions and rival treatments such as Roche’s Vabysmo. The company has been pushing patients toward Eylea HD, a higher-dose version meant to hold market share in retinal disease. Investors also are
Humana Stock Drops After Earnings Beat: Medicare Advantage Headwind Keeps Pressure On

Humana Stock Drops After Earnings Beat: Medicare Advantage Headwind Keeps Pressure On

29 April 2026
Humana beat first-quarter profit estimates, earning $10.31 per share adjusted, but shares fell over 6% premarket after it kept its 2026 profit outlook unchanged and cut its GAAP earnings forecast. Revenue rose to $39.65 billion. The insurer cited lower Medicare Star Ratings for the earnings decline and said medical and pharmacy costs are “slightly better” than expected. Competitors Centene, UnitedHealth, and Elevance recently raised their annual forecasts.
JPMorgan stock slips after the bell as Fed decision looms; what to watch for JPM shares
Previous Story

JPMorgan stock slips after the bell as Fed decision looms; what to watch for JPM shares

AppLovin stock price climbs after Needham upgrade — and earnings are the next test
Next Story

AppLovin stock price climbs after Needham upgrade — and earnings are the next test

Go toTop